Today: 13 June 2026
ServiceNow (NOW) stock slips after hours as CEO contract change nears and $7.75B Armis deal stays in focus
1 January 2026
2 mins read

ServiceNow (NOW) stock slips after hours as CEO contract change nears and $7.75B Armis deal stays in focus

NEW YORK, December 31, 2025, 19:07 ET — After-hours

  • ServiceNow shares fell 0.7% in after-hours trading to $153.19.
  • A Jan. 1-effective CEO contract amendment outlines possible CEO/co-CEO and chair roles through at least 2030.
  • Investors continue to weigh ServiceNow’s planned $7.75 billion all-cash acquisition of cybersecurity firm Armis.

ServiceNow shares fell 0.7% to $153.19 in after-hours trading on Wednesday, which takes place outside the regular 9:30 a.m. to 4 p.m. ET session.

The stock’s late move followed a downbeat finish for Wall Street on the final trading day of 2025. The S&P 500 fell 0.7% and the Nasdaq dropped 0.8% in thin trading, with technology stocks the biggest drag, while the 10-year Treasury yield rose to 4.17%, AP reported.

The timing matters because U.S. stock and bond markets are closed on Thursday for New Year’s Day, a pause that can curb liquidity and leave company-specific catalysts to drive the next move when trading resumes.

A regulatory filing showed ServiceNow amended Chief Executive Bill McDermott’s employment agreement, effective Jan. 1, 2026, extending his service commitment through at least Dec. 31, 2030. The filing said he may serve as CEO or co-CEO, or move into executive or non-executive chairman roles at the board’s discretion, and it also updates CEO severance terms, including benefits tied to a change in control.

ServiceNow last week agreed to buy cyber exposure management firm Armis for about $7.75 billion in cash and expects to fund the transaction with a combination of cash on hand and debt, the company said. The deal is expected to close in the second half of 2026. “ServiceNow is building the security platform of tomorrow,” said Amit Zavery, the company’s president and chief operating officer. ServiceNow Investor Relations

The Armis announcement initially pushed the stock down as investors worried about ServiceNow’s acquisition spree, Reuters reported, against a backdrop of cyberattacks hitting companies from Microsoft to UnitedHealth. “Our security stack, with the acquisition of Armis, is very well positioned, so we won’t need to do any more M&A in security space,” CFO Gina Mastantuono told Reuters. Reuters also said ServiceNow has recently bought security firm Veza, AI company Moveworks and sales automation platform Logik.ai. Reuters

The Armis purchase would broaden ServiceNow’s security workflow push as customers try to map vulnerable devices and automate responses across IT and operational technology — OT, meaning industrial systems that run factories, utilities, and other physical infrastructure. Investors will watch how much leverage the company takes on and how quickly it can turn the deal into revenue growth without pressuring margins.

The McDermott agreement amendment adds a governance angle that can matter for valuation in large-cap software, where leadership continuity and succession planning often influence sales execution and customer confidence. Any signal of a shift toward a co-CEO model would likely draw scrutiny on roles and accountability.

Rate expectations remain a swing factor for high-multiple software stocks. The Federal Reserve’s next policy meeting is scheduled for Jan. 27-28, according to its calendar.

ServiceNow sells subscription software that helps large organizations manage IT services and automate business workflows, and it has been expanding into security and risk tools alongside its broader AI push.

With markets closed Thursday, the next read-through for ServiceNow is likely to hinge on any fresh signals around leadership structure and the timetable and financing of the Armis deal when liquidity returns.

Stock Market Today

  • US-Iran Peace Prospects Boost Stocks Like Crane NXT, PAR Technology, Ryan Specialty
    June 12, 2026, 9:49 PM EDT. Stocks including Ryan Specialty (RYAN), Crane NXT, and PAR Technology rose sharply following a decline in geopolitical tensions after news of a potential US-Iran peace deal. The easing of conflict risk lowered inflation-driven U.S. Treasury yields, dropping 10-year yields and cutting rate hike probability from over 50% to 36%. This improves credit conditions and client confidence, particularly benefiting small and mid-cap business services like Ryan Specialty, which is highly rate-sensitive and reliant on domestic spending. Ryan Specialty shares climbed despite year-to-date losses of nearly 30%, buoyed by insider buying from CFO Janice Hamilton, signaling executive confidence. The stock trades at roughly half its 52-week high but has gained modestly since its 2021 IPO.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026
Previous Story

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop